Hot Topic I. Durability Issue
TAVR Is Better
[Speaker] Duk-Woo Park/Ulsan Univ., Korea
SAVR Is Better
[Speaker] Kyung Hwan Kim/Seoul National Univ., Korea
Discussion
Hot Topic II. Optimal Age Threshold and Indication Expansion (Bicuspid, Moderate AS with HF, Asymptomatic AS)
Interventionist's Perspective
[Speaker] Young-Guk Ko/Yonsei Univ., Korea
Surgeon's Perspective
[Speaker] Sung Ho Jung/Ulsan Univ., Korea
Discussion